A challenging case of stage IV EGFR-mutant lung cancer with histologic transformation and multiple resistance mechanisms

被引：2

作者：

Rivera-Concepcion, Joel ^{[1
]}

Lo, Ying-Chun ^{[2
]}

Uprety, Dipesh ^{[3
]}

Adjei, Alex A. ^{[4
]}

Ernani, Vinicius ^{[5
]}

Leventakos, Konstantinos ^{[6
]}

机构：

[1] Duke Canc Inst, Dept Med Oncol, 20 Duke Med Circle, Durham, NC 27710 USA

[2] Mayo Clin, Dept Lab Med & Pathol, 200 First St SW, Rochester, MN 55905 USA

[3] Wayne State Univ, Barbara Ann Karmanos Canc Inst, Dept Med Oncol, 4100 John R St, Detroit, MI 48201 USA

[4] Cleveland Clin, Taussig Canc Inst, 10201 Carnegie Ave, Cleveland, OH 44106 USA

[5] Mayo Clin, Div Med Oncol, 13400 E Shea Blvd, Scottsdale, AZ 85259 USA

[6] Mayo Clin, Div Med Oncol, 200 First St SW, Rochester, MN 55905 USA

来源：

CURRENT PROBLEMS IN CANCER: CASE REPORTS | 2024年 / 13卷

关键词：

NSCLC; EGFR mutation; Histologic transformation; Acquired resistance; Neuroendocrine cancer; CELL NEUROENDOCRINE CARCINOMA; GEFITINIB PLUS CHEMOTHERAPY; ACQUIRED-RESISTANCE; OSIMERTINIB; PROGRESSION; SURVIVAL; T790M;

D O I：

10.1016/j.cpccr.2024.100284

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

This clinical case presents a patient with NSCLC who experienced on-target resistant mutations and tumor cell transformation from adenocarcinoma to large cell neuroendocrine and small cell carcinoma. Our patient was successfully treated with a combination of targeted therapy, immunotherapy and chemotherapy based on genetic and histologic changes that occurred in a period of five years.

引用

页数：4

共 19 条

[1] Treating disease progression with osimertinib in EGFR-mutated non-small-cell lung cancer: novel targeted agents and combination strategies [J].

Di Noia, V. ;

D'Aveni, A. ;

D'Argento, E. ;

Rossi, S. ;

Ghirardelli, P. ;

Bortolotti, L. . ;

Vavassori, V. ;

Bria, E. ;

Ceresoli, G. L. .

ESMO OPEN, 2021, 6 (06)

[2] Continuation of gefitinib plus chemotherapy prolongs progression-free survival in advanced non-small cell lung cancer patients who get acquired resistance to gefitinib without T790M mutations [J].

Ding, Ting ;

Zhou, Fei ;

Chen, Xiaoxia ;

Zhang, Shijia ;

Liu, Yinan ;

Sun, Hui ;

Ren, Shengxiang ;

Li, Xuefei ;

Zhao, Chao ;

Wang, Heyong ;

Zhou, Caicun .

JOURNAL OF THORACIC DISEASE, 2017, 9 (09) :2923-+

[3] Chemotherapy With Erlotinib or Chemotherapy Alone in Advanced Non-Small Cell Lung Cancer With Acquired Resistance to EGFR Tyrosine Kinase Inhibitors [J].

Goldberg, Sarah B. ;

Oxnard, Geoffrey R. ;

Digumarthy, Subba ;

Muzikansky, Alona ;

Jackman, David M. ;

Lennes, Inga T. ;

Sequist, Lecia V. .

ONCOLOGIST, 2013, 18 (11) :1214-1220

[4] First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer [J].

Horn, L. ;

Mansfield, A. S. ;

Szczesna, A. ;

Havel, L. ;

Krzakowski, M. ;

Hochmair, M. J. ;

Huemer, F. ;

Losonczy, G. ;

Johnson, M. L. ;

Nishio, M. ;

Reck, M. ;

Mok, T. ;

Lam, S. ;

Shames, D. S. ;

Liu, J. ;

Ding, B. ;

Lopez-Chavez, A. ;

Kabbinavar, F. ;

Lin, W. ;

Sandler, A. ;

Liu, S. V. .

NEW ENGLAND JOURNAL OF MEDICINE, 2018, 379 (23) :2220-2229

[5] Transformation to large cell neuroendocrine carcinoma as acquired resistance mechanism of EGFR tyrosine kinase inhibitor [J].

Kogo, Mariko ;

Shimizu, Ryoko ;

Uehara, Keiichiro ;

Takahashi, Yutaka ;

Kokubo, Masaki ;

Imai, Yukihiro ;

Tomii, Keisuke .

LUNG CANCER, 2015, 90 (02) :364-368

[6] Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer [J].

Mok, T. S. ;

Wu, Y. -L. ;

Ahn, M. -J. ;

Garassino, M. C. ;

Kim, H. R. ;

Ramalingam, S. S. ;

Shepherd, F. A. ;

He, Y. ;

Akamatsu, H. ;

Theelen, W. S. M. E. ;

Lee, C. K. ;

Sebastian, M. ;

Templeton, A. ;

Mann, H. ;

Marotti, M. ;

Ghiorghiu, S. ;

Papadimitrakopoulou, V. A. .

NEW ENGLAND JOURNAL OF MEDICINE, 2017, 376 (07) :629-640

[7] Gefitinib Plus Chemotherapy Versus Chemotherapy in Epidermal Growth Factor Receptor Mutation-Positive Non-Small-Cell Lung Cancer Resistant to First-Line Gefitinib (IMPRESS): Overall Survival and Biomarker Analyses [J].

Mok, Tony S. K. ;

Kim, Sang-We ;

Wu, Yi-Long ;

Nakagawa, Kazuhiko ;

Yang, Jin-Ji ;

Ahn, Myung-Ju ;

Wang, Jie ;

Yang, James Chih-Hsin ;

Lu, You ;

Atagi, Shinji ;

Ponce, Santiago ;

Shi, Xiaojin ;

Rukazenkov, Yuri ;

Haddad, Vincent ;

Thress, Kenneth S. ;

Soria, Jean-Charles .

JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (36) :4027-+

[8] RB loss in resistant EGFR mutant lung adenocarcinomas that transform to small-cell lung cancer [J].

Niederst, Matthew J. ;

Sequist, Lecia V. ;

Poirier, John T. ;

Mermel, Craig H. ;

Lockerman, Elizabeth L. ;

Garcia, Angel R. ;

Katayama, Ryohei ;

Costa, Carlotta ;

Ross, Kenneth N. ;

Moran, Teresa ;

Howe, Emily ;

Fulton, Linnea E. ;

Mulvey, Hillary E. ;

Bernardo, Lindsay A. ;

Mohamoud, Farhiya ;

Miyoshi, Norikatsu ;

VanderLaan, Paul A. ;

Costa, Daniel B. ;

Jaenne, Pasi A. ;

Borger, Darrell R. ;

Ramaswamy, Sridhar ;

Shioda, Toshi ;

Iafrate, Anthony J. ;

Getz, Gad ;

Rudin, Charles M. ;

Mino-Kenudson, Mari ;

Engelman, Jeffrey A. .

NATURE COMMUNICATIONS, 2015, 6

[9] Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial [J].

Paz-Ares, Luis ;

Dvorkin, Mikhail ;

Chen, Yuanbin ;

Reinmuth, Niels ;

Hotta, Katsuyuki ;

Trukhin, Dmytro ;

Statsenko, Galina ;

Hochmair, Maximilian J. ;

Ozguroglu, Mustafa ;

Ji, Jun Ho ;

Voitko, Oleksandr ;

Poltoratskiy, Artem ;

Ponce, Santiago ;

Verderame, Francesco ;

Havel, Libor ;

Bondarenko, Igor ;

Kazarnowicz, Andrzej ;

Losonczy, Gyorgy ;

Conev, Nikolay V. ;

Armstrong, Jon ;

Byrne, Natalie ;

Shire, Norah ;

Jiang, Haiyi ;

Goldman, Jonathan W. ;

Batagelj, Emilio ;

Casarini, Ignacio ;

Pastor, Anea Viviana ;

Sena, Susana Noemi ;

Zarba, Juan Jose ;

Burghuber, Otto ;

Hartl, Sylvia ;

Hochmair, Maximilian J. ;

Lamprecht, Bernd ;

Studnicka, Michael ;

Schlittler, Luis Alberto ;

de Oliveira, Fabricio Augusto Martinelli ;

Calabrich, Aknar ;

Girotto, Gustavo Colagiovanni ;

Dos Reis, Peo ;

Gorini, Carlos Fausto Nino ;

De Marchi, Peo Rafael Martins ;

Baldotto, Clarissa Serodio da Rocha ;

Sette, Claudia ;

Zukin, Mauro ;

Conev, Nikolay V. ;

Dudov, Assen ;

Ilieva, Rumyana ;

Koynov, Krassimir ;

Krasteva, Rositsa ;

Tonev, Ivan .

LANCET, 2019, 394 (10212) :1929-1939

[10] Lineage plasticity in cancer: a shared pathway of therapeutic resistance [J].

Quintanal-Villalonga, Alvaro ;

Chan, Joseph M. ;

Yu, Helena A. ;

Pe'er, Dana ;

Sawyers, Charles L. ;

Triparna, Sen ;

Rudin, Charles M. .

NATURE REVIEWS CLINICAL ONCOLOGY, 2020, 17 (06) :360-371

← 1 2 →